FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2599261073> ?p ?o ?g. }

• W2599261073 endingPage "1095" @default.
• W2599261073 startingPage "1087" @default.
• W2599261073 abstract "Purpose To assess the impact on acute toxicity of replacing 5-fluorouracil (5-FU) with capecitabine in definitive chemoradiation for patients with anal squamous cell carcinoma (ASCC). Methods and Materials We retrospectively reviewed the records of 107 consecutive patients with nonmetastatic ASCC treated with definitive chemoradiation from January 2009 to May 2014. In 2011, based on the noninferiority of capecitabine versus 5-FU, our institutional practice shifted to use capecitabine instead of 5-FU for ASCC. Of 107 patients, 63 were treated with infusional 5-FU (1000 mg/m2/day for 4 days) and mitomycin C (MMC) (10 mg/m2) during weeks 1 and 5, and 44 patients were treated with capecitabine (825 mg/m2 twice daily) Monday through Friday throughout radiation therapy (RT) and MMC (10 mg/m2) during weeks 1 and 5. The incidence of grade 3 to 4 acute toxicity was compared between the 2 groups. Results The median age at diagnosis was 59 years, and 78 patients (73%) were female. The patient characteristics were similar between the 2 treatment groups. All patients in both groups were treated with intensity modulated RT (median dose, 56 Gy). In the 5-FU group, 52% experienced grade 3 to 4 neutropenia compared with 20% in the capecitabine group (P=.001). Treatment breaks resulting from toxicity, primarily related to grade 3+ hematologic toxicity, were necessary for 42% of patients treated with 5-FU versus 16% of those treated with capecitabine (P=.006). Conclusions Pelvic radiation therapy with MMC plus capecitabine was well tolerated and appeared to have less grade 3+ acute hematologic toxicity and fewer treatment interruptions than in a population of ASCC patients undergoing definitive chemoradiation with MMC and 5-FU. To assess the impact on acute toxicity of replacing 5-fluorouracil (5-FU) with capecitabine in definitive chemoradiation for patients with anal squamous cell carcinoma (ASCC). We retrospectively reviewed the records of 107 consecutive patients with nonmetastatic ASCC treated with definitive chemoradiation from January 2009 to May 2014. In 2011, based on the noninferiority of capecitabine versus 5-FU, our institutional practice shifted to use capecitabine instead of 5-FU for ASCC. Of 107 patients, 63 were treated with infusional 5-FU (1000 mg/m2/day for 4 days) and mitomycin C (MMC) (10 mg/m2) during weeks 1 and 5, and 44 patients were treated with capecitabine (825 mg/m2 twice daily) Monday through Friday throughout radiation therapy (RT) and MMC (10 mg/m2) during weeks 1 and 5. The incidence of grade 3 to 4 acute toxicity was compared between the 2 groups. The median age at diagnosis was 59 years, and 78 patients (73%) were female. The patient characteristics were similar between the 2 treatment groups. All patients in both groups were treated with intensity modulated RT (median dose, 56 Gy). In the 5-FU group, 52% experienced grade 3 to 4 neutropenia compared with 20% in the capecitabine group (P=.001). Treatment breaks resulting from toxicity, primarily related to grade 3+ hematologic toxicity, were necessary for 42% of patients treated with 5-FU versus 16% of those treated with capecitabine (P=.006). Pelvic radiation therapy with MMC plus capecitabine was well tolerated and appeared to have less grade 3+ acute hematologic toxicity and fewer treatment interruptions than in a population of ASCC patients undergoing definitive chemoradiation with MMC and 5-FU." @default.
• W2599261073 created "2017-04-07" @default.
• W2599261073 creator A5022293657 @default.
• W2599261073 creator A5031539570 @default.
• W2599261073 creator A5034787589 @default.
• W2599261073 creator A5037120205 @default.
• W2599261073 creator A5047439875 @default.
• W2599261073 creator A5054489256 @default.
• W2599261073 creator A5059653684 @default.
• W2599261073 creator A5060393514 @default.
• W2599261073 creator A5062202820 @default.
• W2599261073 creator A5074087271 @default.
• W2599261073 creator A5074410846 @default.
• W2599261073 date "2017-08-01" @default.
• W2599261073 modified "2023-09-30" @default.
• W2599261073 title "Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer" @default.
• W2599261073 cites W1964647842 @default.
• W2599261073 cites W1985456066 @default.
• W2599261073 cites W2008701840 @default.
• W2599261073 cites W2018650910 @default.
• W2599261073 cites W2023667505 @default.
• W2599261073 cites W2037296937 @default.
• W2599261073 cites W2045804591 @default.
• W2599261073 cites W2048787497 @default.
• W2599261073 cites W2056582801 @default.
• W2599261073 cites W2066077329 @default.
• W2599261073 cites W2076341925 @default.
• W2599261073 cites W2084330540 @default.
• W2599261073 cites W2092767351 @default.
• W2599261073 cites W2100671482 @default.
• W2599261073 cites W2116017558 @default.
• W2599261073 cites W2128328462 @default.
• W2599261073 cites W2129300711 @default.
• W2599261073 cites W2146161922 @default.
• W2599261073 cites W2157519739 @default.
• W2599261073 cites W2158244375 @default.
• W2599261073 cites W2269545103 @default.
• W2599261073 cites W2323577539 @default.
• W2599261073 cites W2468095751 @default.
• W2599261073 cites W2537867879 @default.
• W2599261073 doi "https://doi.org/10.1016/j.ijrobp.2017.03.022" @default.
• W2599261073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28721892" @default.
• W2599261073 hasPublicationYear "2017" @default.
• W2599261073 type Work @default.
• W2599261073 sameAs 2599261073 @default.
• W2599261073 citedByCount "43" @default.
• W2599261073 countsByYear W25992610732017 @default.
• W2599261073 countsByYear W25992610732018 @default.
• W2599261073 countsByYear W25992610732019 @default.
• W2599261073 countsByYear W25992610732020 @default.
• W2599261073 countsByYear W25992610732021 @default.
• W2599261073 countsByYear W25992610732022 @default.
• W2599261073 countsByYear W25992610732023 @default.
• W2599261073 crossrefType "journal-article" @default.
• W2599261073 hasAuthorship W2599261073A5022293657 @default.
• W2599261073 hasAuthorship W2599261073A5031539570 @default.
• W2599261073 hasAuthorship W2599261073A5034787589 @default.
• W2599261073 hasAuthorship W2599261073A5037120205 @default.
• W2599261073 hasAuthorship W2599261073A5047439875 @default.
• W2599261073 hasAuthorship W2599261073A5054489256 @default.
• W2599261073 hasAuthorship W2599261073A5059653684 @default.
• W2599261073 hasAuthorship W2599261073A5060393514 @default.
• W2599261073 hasAuthorship W2599261073A5062202820 @default.
• W2599261073 hasAuthorship W2599261073A5074087271 @default.
• W2599261073 hasAuthorship W2599261073A5074410846 @default.
• W2599261073 hasConcept C116263406 @default.
• W2599261073 hasConcept C121608353 @default.
• W2599261073 hasConcept C126322002 @default.
• W2599261073 hasConcept C141071460 @default.
• W2599261073 hasConcept C2776694085 @default.
• W2599261073 hasConcept C2777063308 @default.
• W2599261073 hasConcept C2777909004 @default.
• W2599261073 hasConcept C2779338040 @default.
• W2599261073 hasConcept C2779840525 @default.
• W2599261073 hasConcept C2780456651 @default.
• W2599261073 hasConcept C29730261 @default.
• W2599261073 hasConcept C509974204 @default.
• W2599261073 hasConcept C526805850 @default.
• W2599261073 hasConcept C71924100 @default.
• W2599261073 hasConcept C90924648 @default.
• W2599261073 hasConceptScore W2599261073C116263406 @default.
• W2599261073 hasConceptScore W2599261073C121608353 @default.
• W2599261073 hasConceptScore W2599261073C126322002 @default.
• W2599261073 hasConceptScore W2599261073C141071460 @default.
• W2599261073 hasConceptScore W2599261073C2776694085 @default.
• W2599261073 hasConceptScore W2599261073C2777063308 @default.
• W2599261073 hasConceptScore W2599261073C2777909004 @default.
• W2599261073 hasConceptScore W2599261073C2779338040 @default.
• W2599261073 hasConceptScore W2599261073C2779840525 @default.
• W2599261073 hasConceptScore W2599261073C2780456651 @default.
• W2599261073 hasConceptScore W2599261073C29730261 @default.
• W2599261073 hasConceptScore W2599261073C509974204 @default.
• W2599261073 hasConceptScore W2599261073C526805850 @default.
• W2599261073 hasConceptScore W2599261073C71924100 @default.
• W2599261073 hasConceptScore W2599261073C90924648 @default.
• W2599261073 hasIssue "5" @default.
• W2599261073 hasLocation W25992610731 @default.
• W2599261073 hasLocation W25992610732 @default.

• next